<DOC>
	<DOCNO>NCT00634140</DOCNO>
	<brief_summary>Ezetimibe drug inhibits absorption dietary biliary cholesterol small intestine . Ezetimibe approve use human lower serum cholesterol . The primary aim study determine ezetimibe normalize rest residual volume patient chronic acalculous cholecystitis .</brief_summary>
	<brief_title>The Influence Ezetimibe Gallbladder Function</brief_title>
	<detailed_description>Gallbladder disease continue major healthcare problem United States 750,000 cholecystectomy perform year . In last decade , proportion elective cholecystectomy perform chronic acalculous cholecystitis double . During time , obesity reach epidemic proportion . In addition , obesity-induced visceral steatosis know cause local inflammatory process result organ dysfunction , nonalcoholic steatohepatitis well establish example phenomenon . Previous data lab also show congenital diet-induced obesity result cholecystosteatosis , increase gallbladder wall fat accompany altered gallbladder motility absorption . This phenomenon also document human , patient chronic acalculous and/or calculous cholecystitis increase gallbladder fat nondiseased control . Ezetimibe drug inhibits absorption dietary biliary cholesterol small intestine . Ezetimibe approve use human lower serum cholesterol . Moreover , ezetimibe show ameliorate hepatic steatosis cholesterol gallstone formation animal model . Previous data lab document ezetimibe lower serum cholesterol , prevents biliary crystal ameliorate cholecystosteatosis lean mouse feed high fat diet . However , influence ezetimibe gallbladder motility , absorption accumulation toxic fat , metabolite , cytokine chemokines , cholecystosteatosis , study human . Therefore , aim study 1 ) determine ezetimibe normalize rest residual volume patient chronic acalculous cholecystitis , 2 ) determine ezetimibe normalize gallbladder ion flux patient chronic acalculous cholecystitis 3 ) determine ezetimibe normalize gallbladder absorption/secretion modulators well gallbladder fat , cytokine chemkines . Subjects typical biliary pain ejection fraction le 30 % HIDA scan identify . Patients randomize one group give ezetimibe group give placebo . All subject gallbladder ultrasound study determine volume standardize fatty meal start ezetimibe placebo 4 week . A cholecystectomy perform . In addition , piece gallbladder take cholecystectomy analyzed ion flux , well absorption/secretion modulators accumulation toxic fat , metabolite , cytokine chemokines .</detailed_description>
	<mesh_term>Cholecystitis</mesh_term>
	<mesh_term>Acalculous Cholecystitis</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Subjects typical biliary pain ejection fraction &lt; 30 % HIDA scan . Must &gt; 18 year age . Subjects gallstone see HIDA . Subjects statin medication Subjects know allergy ezetimibe . Subjects pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>gallbladder</keyword>
	<keyword>ezetimibe 4 6 week prior gallbladder removal</keyword>
</DOC>